Newly created CPT codes could help push the adoption of Recor Medical’s renal denervation therapy to treat uncontrolled hypertension.
The American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel created two Category I CPT codes describing renal denervation. The new codes, 37X47 and 37X48, describe percutaneous transcatheter renal sympathetic denervation procedures and are expected to become effective January 1, 2028.
Helen Reeve-Stoffer, Phd, who took the helm as CEO of Recor Medical in August, spoke to
MD+DI
about the codes and what they could mean for the adoption of the firm’s Paradise ultrasound renal denervation system. The technology
won FDA approval in November of 2023
.
Could you talk about the Paradise system and tell us how the device works?
Reeve-Stoffer:
The Paradise system is an ultrasound-based renal denervation system approved in the US for treating high blood pressure. It uses femoral balloon technology placed inside the renal artery. Ultrasound energy is delivered into the tissue to reduce nervous activity of the nerves going to the kidney.
The transducer sits inside a balloon filled with cooling water, which protects the inside of the renal artery while the treatment is administered. This reduction in nervous activity lowers blood pressure. The procedure involves placing the catheter, delivering two or three very short ablations—just 7 seconds each—and then removing the catheter to treat the other kidney. It's a bilateral procedure. The process is simple, quick, and multiple clinical studies have demonstrated its effectiveness in reducing blood pressure.
How would the approval of the codes be beneficial for Recor?
Reeve-Stoffer:
Renal denervation currently sits under a Category 3 code, which is typically established when new technologies are in an investigational phase to provide some level of reimbursement.
The conversion to Category 1 is really meaningful because it supports the fact that this technology is now moving into standard of care and out of the clinical investigational phase. For renal denervation in general, and for us as a renal denervation company, it represents acceptance that our investigational therapy is transitioning into the standard of care.
What specific criteria did the AMA CPT editorial panel use to determine that renal denervation qualified for Category 1 CPT codes rather than remaining in Category 3?
Reeve-Stoffer:
While it's difficult to know exactly what influenced their decision, the panel considers several factors. They review clinical evidence around the therapies—we provided extensive clinical data supporting the technology's effectiveness in reducing blood pressure. They also evaluate what they call "widespread use," looking at the number of patients treated and physicians using the technology, comparing it with disease prevalence. This helps them determine whether the technology has moved from the investigational phase into the standard of care. The applicants, ACC and SCAI, compiled and presented this data to the AMA during the panel meeting.
How does the Paradise ultrasound renal denervation system differ from other renal denervation technologies in development or use?
Helen Reeve-Stoffer:
Our technology only treats the main renal artery. The other currently approved technology—Medtronic's [Symplicity]—has to treat in the distal branches, moving through the main renal artery and into each distal branch.
Technologies in development are a mix of both approaches. For example, the
Sonovie system, purchased by Boston Scientific
, treats mainly in the main renal artery. Other devices, like one by Biosensors, also treat distally. This is why there are two codes—they're related to where treatment occurs: main artery only versus main artery plus distal branches. This categorizes the two different treatment strategies.
So, with the code you recently got approval for, Medtronic's approved technology wouldn't fall under this same code, correct?
Reeve-Stoffer:
There are two codes. One covers us, and one covers Medtronic based on how the technology works. Simply put, there's one for each of us.
Could you talk about some highlights of the clinical trial data that supported FDA approval of Paradise?
Helen Reeve-Stoffer:
When we first started looking at the Paradise system during randomized clinical trials, we ran three different trials in different hypertensive patient populations. We were able to show that blood pressure reduction in patients was significantly greater if you treated them with our system versus if you just gave them a sham procedure. That's really the early evidence of there being a real effect of renal denervation.
The blood pressure drops in those trials were around 10 millimeters of mercury systolic, which is significantly meaningful from a cardiovascular risk perspective. But perhaps even more important is that after three years of collecting real-world clinical evidence—what the device does in the commercial population—we're actually seeing even larger drops in blood pressure, up to 20 millimeters of mercury, which we recently published. There will be a lot more data presented at TCT in the next couple of weeks across the renal denervation space in general, which will be very meaningful to show not only that we're getting substantial drops in blood pressure, but that those blood pressure changes are maintained over time. That's really important for patients as they try to reduce their cardiovascular risk.
Why aren't we seeing more adoption of this therapy? Do you feel like you have to do an education piece and really hammer that home to physicians and patients?
Helen Reeve-Stoffer:
I think there are two reasons why adoption is not where we both think it should be right now. First, it's the history of the therapy. The previous 12 years—we're still battling with the misconception that the therapy doesn't work, which is probably pretty crazy for both of us, but it's real.
The other part is unfortunately more financial. Especially in the US, access to medical care is all around what is reimbursed, and we're still in the very early stages of getting this to be a procedure that is routinely reimbursed.
The great news is that as of last year, CMS initiated the national coverage determination for the therapy, so there's coverage for Medicare patients. But there's still some resistance from commercial payers for multiple reasons. First, because it's Category 3, in their mind it's still investigational or experimental. They're also using some of the history of the therapy to suggest they don't believe it should be fully reimbursed yet.
I think that's where this Category 1 conversion will be very helpful. As it's now being considered more standard of care and the codes come into effect in 2028—we're not expecting immediate impact—but hopefully as 2028 comes in, commercial payers will start to also cover and pay for this therapy. Then I think adoption will start to be exactly where we see it should be.